Peregrine Pharmaceuticals reported $62K in Ordinary Share Capital for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ordinary Share Capital Change
Agenus AGEN:US USD 2.95M 120K
Amgen AMGN:US USD 32.37B 1.03B
AstraZeneca AZN:LN USD 387M 0
Bristol Myers Squibb BMY:US USD 292M 0
Celldex Therapeutics CLDX:US USD 47K 0
Eli Lilly And LLY:US USD 594.1M 0
GlaxoSmithKline GSK:LN GBP 1.35B 0
Immunogen IMGN:US USD 2.21M 2K
Karyopharm Therapeutics KPTI:US USD 8K 0
Macrogenics MGNX:US USD 615K 0
Mannkind MNKD:US USD 2.63M 59K
Minerva Neurosciences NERV:US USD 1000 0
Newlink Genetics NLNK:US USD 83K 0
Novartis NOVN:VX USD 878.25M 11.75M
Novavax NVAX:US USD 792K 4K
Peregrine Pharmaceuticals PPHM:US USD 62K 0
Repligen RGEN:US USD 555K 0
Xencor XNCR:US USD 598K 0